aceRNA Technologies specializes in developing cutting-edge RNA switch technology aimed at creating novel therapies for diseases that currently lack effective treatments. The company operates in the biotechnology sector, focusing on the development of mRNA medicines that can be precisely controlled at the cellular level. This technology allows for targeted therapeutic effects, minimizing impact on non-target cells and enhancing both safety and efficacy. aceRNA Technologies serves pharmaceutical companies and research institutions, providing them with advanced tools for mRNA expression control. The business model includes collaboration agreements, such as the notable partnership with Pfizer, and the sale of RNA switch research reagents. Revenue is generated through these collaborations and product sales. The company has secured funding from prominent investors, including Kyoto University Innovation Capital and SMBC Venture Capital, to further its research and development efforts.

Keywords: RNA switch, mRNA therapies, biotechnology, targeted treatment, cell-specific, Pfizer collaboration, therapeutic innovation, research reagents, venture capital, precision medicine.